Reimold M, la Fougère C
Abteilung Nuklearmedizin und Klinische Molekulare Bildgebung, Department Radiologie, Universitätsklinikum Tübingen, Otfried-Müller-Str. 14, 72076, Tübingen, Deutschland.
Radiologe. 2016 Jul;56(7):580-7. doi: 10.1007/s00117-016-0124-8.
In neurodegeneration and in neuro-oncology, the standard imaging procedure, magnetic resonance imaging (MRI), shows limited sensitivity and specificity. Molecular imaging with specific positron-emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers allows various molecular targets and metabolic processes to be assessed and is thus a valuable adjunct to MRI. Two important examples are referred to here: amino acid transport for neuro-oncological issues, and the recently approved PET tracers for detecting amyloid depositions during the preclinical stage of Alzheimer's disease. This review discusses the clinical relevance and indications for the following nuclear medicine imaging procedures: amyloid PET, (18)F-fluorodeoxyglucose (FDG)-PET, and dopamine transporter (DaT)-SPECT for the diagnosis of dementia and the differential diagnosis of Parkinson's disease, in addition to amino acid PET for the diagnosis of brain tumors and somatostatin receptor imaging in meningioma.
在神经退行性疾病和神经肿瘤学中，标准成像程序磁共振成像（MRI）的敏感性和特异性有限。使用特定正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）示踪剂的分子成像能够评估各种分子靶点和代谢过程，因此是MRI的重要辅助手段。这里提及两个重要例子：用于神经肿瘤问题的氨基酸转运，以及最近获批用于在阿尔茨海默病临床前阶段检测淀粉样蛋白沉积的PET示踪剂。本综述讨论了以下核医学成像程序的临床相关性和适应症：用于痴呆诊断和帕金森病鉴别诊断的淀粉样蛋白PET、（18）F-氟脱氧葡萄糖（FDG）-PET和多巴胺转运体（DaT）-SPECT，以及用于脑肿瘤诊断的氨基酸PET和脑膜瘤中的生长抑素受体成像。
